Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: Antiamphetamine effects and extrapyramidal side effects

Neuropsychopharmacology

Volumn 20, Issue 1, 1999, Pages 35-43

  Peacock, L ^a   Hansen, L ^a   Morkeberg F ^a   Gerlach, J ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Amphetamine; Dopamine D1 antagonists; Dopamine D2 antagonists; Dyskinesia; Dystonia; Extrapyramidal side effects; Monkeys

Indexed keywords

8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; AMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; BRADYKINESIA; CEBIDAE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; STEREOTYPY;

AMPHETAMINE; ANIMALS; AROUSAL; BASAL GANGLIA DISEASES; BENZAZEPINES; BENZOFURANS; CEBUS; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; DYSTONIA; MALE; MOTOR ACTIVITY; RACLOPRIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; STEREOTYPED BEHAVIOR;

EID: 0032916510     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00049-9     Document Type: Article

References (36)

1. Barnes T.R.E., Gerlach J. D1 receptor antagonists in schizophrenia. Psychopharmacology. 121:1995;287-288.
2. Casey D.E. The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys. Psychopharmacology. 121:1995;289-293.
3. Christensen A.V. Long-term effects of dopamine D1 and D2 antagonists in vervet monkeys. Behavioral Neurol. 3:1990;49-60.
4. Coffin V.L., Latranyi M.B., Chipkin R.E. Acute extrapyramidal syndromes in Cebus monkeys. Development mediated by dopamine D2 but not D1 receptors J Pharmacol Exp Ther. 249:1989;769-774.
5. Collins P., Broekkamp C.L.E., Jenner P., Marsden C.D. Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology. 103:1991;503-512.
6. Coward D.M., Imperato A., Urwyler S., White T.G. Biochemical and behavioral properties of clozapine. Psychopharmacology. 99:1989;S6-S12.
7. Daly S.A., Waddington J.L. Behavioral evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 69930 and isoquinoline antagonist BW737C. Psychopharmacology. 113:1993;45-50.
8. Daly S.A., Waddington J.L. The effects of clozapine on behavioral responses to the selective "D1-like" dopamine receptor agonist, A 68930, and to the selective "D2-like" agonist, RU 24213. Br J Pharmacol. 133:1994;839-844.
9. de Beaurepaire R., Labelle A., Naber D., Jones B.D., Barnes T.R.E. An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology. 121:1995;323-2721.
10. Den Boer J.A., van Megan H.J.G.M., Fleischhacker W.W., Louwerens J.W., Slaap B.R., Westenberg H.G.M., Burrows G.D., Srivastava O.N. Differential effects of the D1-DA receptor antagonist SCH 39166 on positive and negative symptoms of schizophrenia. Psychopharmacology. 121:1995;317-322.
11. Deveney A.M., Waddington J.L. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to "D1-like" dopamine receptors not linked to adenylyl cyclase. Br J Pharmacol. 116:1995;2120-2126.
12. Downes R.P., Waddington J.L. Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine "D1-like" receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur J Pharmacol. 234:1993;135-136.
13. Ellenbroek B., Willemen A., Cools A. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology. 2:1989;191-199.
14. Farde L., Nordstrom A.-L., Wiesel F.-A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatr. 49:1992;538-544.
15. Gerlach J. New antipsychotics. Classification, efficacy, and adverse effects Schizophr Bull. 17:1991;289-309.
16. Gerlach J., Hansen L. Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatr. 160:1992;34-37.
17. Gerlach J., Hansen L. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys. Dystonia, Dyskinesia, and D1-D2 supersensitivity J Psychopharm. 7:1993;355-364.
18. Giambalvo C.T., Wagner R.L. Activation of D1 and D2 dopamine receptors inhibits protein kinase C activity in striatal synaptosomes. J Neurochem. 63:1994;168-176.
19. Glenthøj B., Bolwig T.G., Hemmingsen R. Effects of chronic discontinuous and chronic continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756). Eur J Pharmacol. 242:1993;281-291.
20. Kakigi T., Gao X.-M., Tamminga C.A. Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J Neural Transm (Gen Sect). 101:1995;41-49.
21. Karle J., Clemmesen L., Hansen L., Andersen M., Andersen J., Fensbo C., Sloth-Nielsen M., Skrumsager B., Lublin H., Gerlach J. NNC 01-687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology. 121:1995;328-329.
22. Karlsson P., Smith L., Farde L., Harnryd C., Sedvall G., Wiesel F.-A. Lack of apparent antipsychotic effect of the D1 dopamine receptor antagonist SCH 39166 in acutely ill schizophrenic patients. Psychopharmacology. 121:1995;309-316.
23. Latinen J.T. Dopamine stimulates K+ efflux in the chick retina via D1 receptors independently of adenelyl cyclase activation. J Neurochem. 61:1993;1461-1469.
24. Lublin H., Gerlach J., Peacock L. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity Psychopharmacology. 112:1993;389-397.
25. Lublin H., Gerlach J., Mørkeberg F. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists. Psychopharmacology. 114:1994;495-504.
26. Mailman R.B., Schulz D.W., Kilts C.D., Lewis M.H., Rollema H., Wyrick S. Biochemical and functional studies of D-1 dopamine receptors. Psychopharmacol Bull. 22:1986;593-598.
27. McHugh D., Coffin V. The reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist. Eur J Pharmacology. 202:1991;133-134.
28. Nielsen E., Andersen P. Dopamine receptor occupancy in vivo. Behavioral correlates using NNC-112, NNC-687, and NNC-756, new selective D-1 Receptor antagonists Eur J Pharmacol. 219:1992;35-41.
29. Nordic Dyskinesia Study Group Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixine, perphenazine, haloperidol, and haloperidol + biperiden Psychopharmacology. 90:1986;423-429.
30. Peacock L., Gerlach J. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. Eur J Pharmacol. 237:1993;329-340.
31. Peacock L., Gerlach J. A reanalysis of the dopamine theory of tardive dyskinesia. The hypothesis of dopamine D1/D2 imbalance Yassa R., Nair N.P.V., Jeste D.V. Neuroleptic-Induced Movement Disorders. 1997;141-160 Cambridge University Press, Cambridge.
32. Peacock L, Gerlach J (in press) New and old antipsychotics versus clozapine in a monkey model: Adverse effects and antiamphetamine effects. Psychopharmacology.
33. Rogers D.C., Hunter A.J., Hill R.G. Relationship between behavioral activation and adenylate cyclase activity induced by the dopamine D1 receptor agonists 80723, 83565, and 83959. Soc Neurosci Abstr. 16:1990;1054.
34. Undie A.S., Weinstock J., Sarau H.M., Friedman E. Evidence for a distinct D1-like receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem. 62:1994;2045-2048.
35. Wachtel S.R., White F.J. The D1 dopamine receptor antagonist SCH 23390 exerts agonist-like effects on rat nucleous accumbens neurons. Soc Neurosci Abstr. 17:1991;1353.
36. Waddington J.L. Pre- and postsynaptic D1 and D5 receptor mechanisms in relation to antipsychotic activity. Barnes T. Antipsychotic Drugs and Their Side Effects. 1993;66-85 Academic Press, San Diego.